MiMedx Group, Inc. (NASDAQ:MDXG) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of MiMedx Group, Inc. (NASDAQ:MDXG) have been given an average recommendation of “Buy” by the five analysts that are covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $12.00.

MDXG has been the subject of several research reports. Craig Hallum dropped their target price on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $11.00 price objective on shares of MiMedx Group in a research report on Thursday, August 1st. Finally, StockNews.com cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 15th.

MiMedx Group Price Performance

NASDAQ MDXG opened at $5.71 on Friday. The stock’s fifty day moving average price is $6.12 and its 200 day moving average price is $6.69. The company has a market cap of $842.82 million, a price-to-earnings ratio of 12.98 and a beta of 1.97. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.85 and a quick ratio of 3.22. MiMedx Group has a 1 year low of $5.47 and a 1 year high of $9.27.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.08. The business had revenue of $87.21 million for the quarter, compared to analyst estimates of $88.44 million. MiMedx Group had a net margin of 23.63% and a return on equity of 34.24%. As a group, equities research analysts forecast that MiMedx Group will post 0.26 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Isthmus Partners LLC raised its position in shares of MiMedx Group by 30.4% during the 2nd quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock worth $27,000 after purchasing an additional 91,714 shares during the period. Headlands Technologies LLC bought a new position in MiMedx Group during the 1st quarter valued at $27,000. Blue Trust Inc. bought a new stake in shares of MiMedx Group during the 3rd quarter worth $30,000. Point72 Asset Management L.P. bought a new stake in shares of MiMedx Group during the 2nd quarter worth $40,000. Finally, Quest Partners LLC bought a new stake in shares of MiMedx Group during the 2nd quarter worth $81,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.